Table 4 Scores of Behcet’s Disease Current Activity Form (BDCAF)
From: Identification of the immune-related biomarkers in Behcet’s disease by plasma proteomic analysis
Overall | Cluster 1 | Cluster 2 | p | |
|---|---|---|---|---|
n | 26 | 14 | 12 | |
Sex (%) | ||||
Female | 13 (50.0) | 5 (35.7) | 8 (66.7) | 0.238 |
Male | 13 (50.0) | 9 (64.3) | 4 (33.3) | |
Age (mean (SD)) | 33.04 (14.37) | 22.57 (7.70) | 45.25 (9.84) | < 0.001 |
Disease duration (months) (median (Q1, Q3)) | 37.0 (24.0–75.0) | 24.0 (17.25–54.50) | 80.0 (36.0–215.2) | 0.022 |
Treatment (yes, %) | 7 (26.90) | 4 (28.6%) | 3 (25.0) | 1.000 |
Headaches (%) | 7 (26.9) | 5 (35.7) | 2 (16.7) | 0.517 |
Mouth ulcers (%) | 19 (73.1) | 13 (92.9) | 6 (50.0) | 0.044 |
Genital ulcers (%) | 14 (53.8) | 10 (71.4) | 4 (33.3) | 0.122 |
Erythema nodosum (%) | 11 (42.3) | 7 (50.0) | 4 (33.3) | 0.646 |
Pustules (%) | 7 (26.9) | 5 (35.7) | 2 (16.7) | 0.517 |
Arthralgia (%) | 5 (19.2) | 2 (14.3) | 3 (25.0) | 0.848 |
Arthritis (%) | 4 (15.4) | 1 (7.1) | 3 (25.0) | 0.476 |
Nausea/vomiting (%) | 6 (23.1) | 3 (21.4) | 3 (25.0) | 1.000 |
Diarrhea (%) | 1 (3.8) | 1 (7.1) | 0 (0.0) | 1.000 |
Any eye problems (%) | 14 (53.8) | 6 (42.9) | 8 (66.7) | 0.413 |
Any new CNS activity (%) | 2 (7.7) | 1 (7.1) | 1 (8.3) | 1.000 |
Any new major vascular activity (%) | 2 (7.7) | 1 (7.1) | 1 (8.3) | 1.000 |
BDCAF (mean (SD)) | 3.54 (1.45) | 3.93 (1.44) | 3.08 (1.38) | 0.141 |